CytoMed Therapeutics rises on US patent for its technology

CytoMed Therapeutics

06/07/2023 12:59

** Shares of cell-based immunotherapy developer CytoMed
Therapeutics  GDTC.O  rise 7.86% to $3.31 premarket
    ** The Singapore-based company says its CAR-gamma delta
(CAR-γδ) T cell technology, exclusively licensed from
Singapore's Agency for Science, Technology and Research, has
been granted a patent by the U.S. Patent and Trademark Office
    ** Company holds an exclusive, worldwide license, for use on
immunotherapy, including stem cell therapy, until the expiration
of the patent covering technology
    ** GDTC's CAR-γδ T cell technology is currently being
developed as an investigational cancer therapy to target NKG2D
ligands, a type of stress-induced cancer antigens
    ** Up to last close, stock down ~23% since it went public on
April 14 this year

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))